Business Description
MetaVia Inc
NAICS : 325412
SIC : 2834
ISIN : US64132R4048
Total Employee Number:
8Description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 70.78 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 73.3 | |||||
3-Year EPS without NRI Growth Rate | 74.8 | |||||
3-Year FCF Growth Rate | 72 | |||||
3-Year Book Growth Rate | -68.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 37.15 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.07 | |||||
9-Day RSI | 32.4 | |||||
14-Day RSI | 38.59 | |||||
3-1 Month Momentum % | 135.92 | |||||
6-1 Month Momentum % | -66.38 | |||||
12-1 Month Momentum % | -59.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.73 | |||||
Quick Ratio | 2.73 | |||||
Cash Ratio | 2.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -99.9 | |||||
Shareholder Yield % | -251.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -188.9 | |||||
ROA % | -92.61 | |||||
ROIC % | -1298.24 | |||||
3-Year ROIIC % | 24.44 | |||||
ROC (Joel Greenblatt) % | -8676.07 | |||||
ROCE % | -197.49 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 0.81 | |||||
EV-to-EBIT | 0.44 | |||||
EV-to-Forward-EBIT | -0.03 | |||||
EV-to-EBITDA | 0.44 | |||||
EV-to-FCF | 0.41 | |||||
| Price-to-Net-Current-Asset-Value | 0.84 | |||||
| Price-to-Net-Cash | 0.88 | |||||
Earnings Yield (Greenblatt) % | 227.27 | |||||
FCF Yield % | -205.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MTVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MetaVia Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.61 | ||
| Beta | 3.0729 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.57 | ||
| Volatility % | 154.54 | ||
| 14-Day RSI | 38.59 | ||
| 14-Day ATR ($) | 0.263067 | ||
| 20-Day SMA ($) | 1.8735 | ||
| 12-1 Month Momentum % | -59.99 | ||
| 52-Week Range ($) | 0.9661 - 19.0289 | ||
| Shares Outstanding (Mil) | 5.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MetaVia Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MetaVia Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| Virtual Investor Conferences | 2026-06-24 10:30 | 1.54 (+1.32%) | ||
| Emerging Growth Conference | 2026-06-11 15:25 | 1.96 (+7.10%) | ||
| General meeting for 2026 | 2026-06-08 10:00 | 2.57 (-3.02%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.20 (+23.58%) | ||
| Annual report for 2025 | 2026-03-26 | 1.30 (+4.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.30 (+4.00%) | ||
| Life Sciences Virtual Investor Forum | 2026-03-12 10:30 | 1.63 (+5.50%) | ||
| Emerging Growth Conference | 2026-02-25 10:15 | 1.60 (+3.23%) |
Show
Entries
MetaVia Inc Frequently Asked Questions
What is MetaVia Inc(MTVA)'s stock price today?
The current price of MTVA is $1.43. The 52 week high of MTVA is $19.03 and 52 week low is $0.97.
When is next earnings date of MetaVia Inc(MTVA)?
The next earnings date of MetaVia Inc(MTVA) is 2026-08-07 Est..
Does MetaVia Inc(MTVA) pay dividends? If so, how much?
MetaVia Inc(MTVA) does not pay dividend.
Guru Commentaries on NAS:MTVA
No articles.
Press Release
Articles on MetaVia Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers